Literature DB >> 21821007

Induction of diabetes with signs of autoimmunity in primates by the injection of multiple-low-dose streptozotocin.

Lingling Wei1, Yanrong Lu, Sirong He, Xi Jin, Li Zeng, Shuang Zhang, Younan Chen, Bole Tian, Gang Mai, Guang Yang, Jie Zhang, Li Wang, Hongxia Li, James F Markmann, Jingqiu Cheng, Shaoping Deng.   

Abstract

AIM: To develop a preclinical large animal model of autoimmune diabetes to facilitate the translational research of autoimmune diabetes in human.
MATERIALS AND METHODS: Nine young rhesus monkeys received multiple-low-dose (MLD) intravenous injections of streptozotocin for five consecutive days, followed by two additional boosting injections of STZ given 1 week apart. The induction of autoimmune diabetes was evaluated by regular metabolic testing, serological assessment of islet-reactive autoantibodies and histological examination of pancreatic tissues.
RESULTS: Seven of nine treated animals became diabetic with moderate hyperglycemia initially and more severe hyperglycemia thereafter. All diabetic animals exhibited severely impaired glucose tolerance, limited islet function, and required insulin therapy to maintain relatively normal glucose metabolism and healthy status. Serological tests showed that all diabetic monkeys developed autoantibodies specifically against insulin and islet antigens. Furthermore, histological examination of the pancreata from diabetic animals revealed evidence of specific destruction of islet β cells and islets infiltrated with T lymphocytes. Overt and persistent diabetes can be induced in young rhesus monkeys by the injection of MLD-STZ, and autoimmune responses to pancreatic islet cells seem to be involved in the development of glucose intolerance and diabetes.
CONCLUSION: These data indicate for the first time that autoimmune diabetes can be induced in primates; this may serve as a valuable preclinical model for studying the pathogenesis of and potential therapies for autoimmune diabetes in humans.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821007     DOI: 10.1016/j.bbrc.2011.07.105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Successful pharmaceutical-grade streptozotocin (STZ)-induced hyperglycemia in a conscious tethered baboon (Papio hamadryas) model.

Authors:  Patrice A Frost; Shuyuan Chen; Marguerite J Mezzles; Venkata Saroja Voruganti; Edna J Nava-Gonzalez; Hector E Arriaga-Cazares; Katy A Freed; Anthony G Comuzzie; Ralph A DeFronzo; Jack W Kent; Paul A Grayburn; Raul A Bastarrachea
Journal:  J Med Primatol       Date:  2015-06-30       Impact factor: 0.667

2.  The use of animal models in diabetes research.

Authors:  Aileen J F King
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Streptozotocin-induced cytotoxicity, oxidative stress and mitochondrial dysfunction in human hepatoma HepG2 cells.

Authors:  Haider Raza; Annie John
Journal:  Int J Mol Sci       Date:  2012-05-11       Impact factor: 6.208

4.  The Combined Extract of Zingiber officinale and Zea mays (Purple Color) Improves Neuropathy, Oxidative Stress, and Axon Density in Streptozotocin Induced Diabetic Rats.

Authors:  Jintanaporn Wattanathorn; Paphaphat Thiraphatthanavong; Supaporn Muchimapura; Wipawee Thukhammee; Kamol Lertrat; Bhalang Suriharn
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-12       Impact factor: 2.629

5.  Elucidation of Molecular Mechanisms of Streptozotocin-Induced Oxidative Stress, Apoptosis, and Mitochondrial Dysfunction in Rin-5F Pancreatic β-Cells.

Authors:  Arwa M T Al Nahdi; Annie John; Haider Raza
Journal:  Oxid Med Cell Longev       Date:  2017-08-06       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.